Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2006

View Archived Issues

sanofi-aventis reviews Q4 fortunes

Preclinical studies evaluate the activity of PPP in multiple myeloma

Structure analysis reveals binding of JAK2 and JAK inhibitor

Antiplatelet activity of MRS-2500 observed ex vivo and in vivo

Patupilone safe, well tolerated in patients with advanced solid tumors

Medivir acquires Cathepsin S inhibitor project rights from Peptimmune

New phase I/II study assesses sublingual vaccines with MPL adjuvant for allergy

Takeda granted rights for Hematide in Japan

Immtech licenses aminoquinoline drugs from Tulane University

Vaccinex enters antibody collaboration with Schering AG

Panvac-VF phase III study completes enrollment

QR-435 demonstrates antiviral activity against ocular and genital herpes

Schering AG exercises option for gadofluorine derivative in Epix collaboration

Cangene awarded funding to develop PEG-GM-CSF for acute radiation syndrome

Amgen and Biovitrum expand type 2 diabetes and metabolic disease agreement

Replidyne and Forest enter U.S. agreement for faropenem medoxomil

Garenoxacin NDA accepted for review

NCI to study CTCE-9908 for primary effusion lymphoma

Fast track designation for tesmilifene for advanced breast cancer

Nalbuphine ER reduces pain intensity in dose-dependent manner

FDA warns on risks of aprotinin

DEBIO-025 well tolerated in HIV-1 infected subjects

MK-0518 active, well tolerated in resistant HIV-1 infection

TNX-355 targets HIV in a tropism-independent manner

New N-type calcium channel blockers emerge from Ajinomoto

Aricept sNDA accepted for review

AstraZeneca withdraws Exanta

Novel therapeutics for neurological disorders reported in recent patent literature

Recent patents impart novel agents for respiratory disorders

Recent Ono patent reports new coagulation factor Xa inhibitors